Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Loperamide × Clear all
NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Eli Lilly and Company

Phase 1 Active not recruiting
198 enrolled
Breast

Breast Neoplasms

NCT05252546 2022-12-23

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡